Purchase this article with an account.
Michael Rafaelof, Andrew A Moshfeghi, Laurens Bouckaert, Nick Boucher, Namrata Saroj; Assessment of Eyes with Non-Exudative Age-Related Macular Degeneration in US Retina Practices. Invest. Ophthalmol. Vis. Sci. 2020;61(7):4175.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the epidemiology of eyes with non-exudative (dry) age-related macular degeneration (AMD) in US retina practices.
Retrospective study of electronic medical records obtained from Vestrum Health Retina Database, a geographically diverse sample of US retina providers. Eyes with a diagnosis of dry AMD based on the associated ICD-10 diagnosis codes between 2017 and 2018 were included. Only the first encounter, where the primary disease diagnosis was identified for each patient eye, is included. The primary aim of the study was to identify the proportion of eyes categorized with early, intermediate, advanced (geographic atrophy) and unspecified dry AMD. For those eyes that could have at least one year of follow-up, disease progression between the different categories, conversion to neovascular AMD and proportion of eyes with vision loss were noted.
Of a total of 866,952 eyes, 142,151 (16%) were determined to have dry AMD, of which 45,898 (32%), 65,711 (46%), 13,979 (10%), 16,563 (12%) were identified as early, intermediate, advanced, and unspecified dry AMD, respectively. Of the eyes that could have > 1 year of follow-up, the majority of the eyes (58% - 65%) remained stable. The rate of conversion to neovascular AMD was 2%, 6%, and 6% in eyes originally diagnosed with early, intermediate and advanced dry AMD, respectively. 32% of the eyes did not have a follow-up visit within the year. Proportions of eyes losing > 1 line of vision during the first year of follow-up were 21%, 26%, and 36% in eyes with early, intermediate and advanced dry AMD.
A large retrospective review of data from multiple US retina practices indicates that the majority of eyes with dry AMD are initially diagnosed with intermediate dry AMD at these sites. Most eyes remained stable during the first year of follow-up and the proportion of eyes with vision loss increased with severity level.
This is a 2020 ARVO Annual Meeting abstract.
This PDF is available to Subscribers Only